Macuject Is Putting an AI Fluid Meter in Front of Wet AMD Clinics

For ophthalmologists treating wet age-related macular degeneration, the difference between preserving sight and losing it can come down to a few microliters of fluid. The standard diagnostic tool, optical coherence tomography (OCT), generates detailed 3D scans of the retina. But quantifying the fluid within those scans, and deciding whether to inject expensive anti-VEGF drugs, remains a manual, subjective, and time-consuming step. A clinician-founded Australian startup, Macuject, is betting that a cloud-based AI assistant can bring consistency and efficiency to this high-stakes process [Macuject.com].

The clinician's decision tree

Macuject's core product is a SaaS platform that ingests OCT scans and uses proprietary algorithms to perform quantitative macular fluid analysis. The output is not just a measurement, but a structured patient dashboard and a customizable clinical decision tree designed to guide treatment. The goal is to reduce variability between clinicians and help busy practices manage growing patient loads more effectively. Founder Dr. Devinder Chauhan, an ophthalmologist, built the system from within the clinic, aiming to address the specific workflow bottlenecks he encountered [Bionics Institute]. The company has been in a beta testing phase with a select group of ophthalmologists since at least May 2021 [mivision 2021].

A lean team with a compliance milestone

Public information on the team is limited, but the executives named in profiles suggest a focus on commercialization and technical rigor. Dr. Chauhan provides the clinical foundation. The operational side includes Peter Girling as COO, previously a co-founder and CEO at CELLnTEC, and Adam Wardell as Chief Commercialisation Officer [Crunchbase]. On the technical front, CTO Bradley Beddoes, who previously led technology at the Australian Access Federation, has overseen a key milestone: achieving SOC2 and HIPAA compliance for the platform [Bradley Beddoes LinkedIn]. This is a non-negotiable prerequisite for handling protected health information, particularly for any future expansion into the US market, which the company has cited as a target [Medium Verge Healthtech].

The funding and regulatory path

To date, Macuject has reported raising approximately $620,000 in total funding [HealthTechAlpha]. It has participated in the ANDHealth+ accelerator program, a Australian digital health incubator [Macuject.com/blog-pages/andhealth-plus]. The capital appears directed at two clear objectives: completing the clinical decision-making logic for diabetic macular oedema, another fluid-related retinal disease, and pursuing regulatory clearance from the United States Food and Drug Administration for its web application [mivision 2022]. The regulatory pathway for software as a medical device (SaMD) is well-defined but demanding, requiring robust clinical validation. Macuject's current use appears confined to private clinics in Australia, serving as a real-world testing ground before a regulated launch.

The competitive and clinical landscape

Macuject operates in a niche with established players and similar startups. Competitors include RetinAI, Notal Vision, and RetInSight, each with their own approaches to retinal image analysis and remote monitoring [CBInsights]. The company's early wedge seems to be its clinician-driven design and focus on integrating directly into the treatment decision workflow, rather than just providing analytics. However, the road to widespread adoption is paved with significant challenges.

• Clinical validation. While beta testing is a start, peer-reviewed studies demonstrating improved patient outcomes or superior accuracy against expert graders are the currency of credibility in medical AI. These are not yet public.
• Commercial traction. The company has not named any clinic, healthcare organization, or OEM customers. Rolling out in a fragmented private practice market requires a sales motion and proof of return on investment that are unproven.
• Regulatory clock. FDA review is a resource-intensive process measured in years, not months. Progress here will be the single most important signal of the company's technical and operational maturity.

For the estimated 20 million people worldwide with age-related macular degeneration, the current standard of care is a burdensome cycle. It typically involves monthly or bimonthly clinic visits for OCT scans and intravitreal injections, a regimen that strains healthcare systems and patients alike. Treatment decisions are often based on a qualitative "gestalt" read of the scan. Macuject's proposition is to replace that ambiguity with a quantified, repeatable metric, potentially enabling more precise dosing and longer intervals between treatments. If the AI performs as intended, the benefit is straightforward: less fluid, fewer injections, and more preserved vision for patients.

What to watch next

The next twelve months should reveal whether Macuject can transition from a promising clinician's tool to a commercial medical device. Key milestones will be the submission of an FDA application, the publication of any validation data, and the announcement of a first named commercial partnership or pilot with a clinic network or OCT manufacturer. The company's ability to secure additional funding to see through the regulatory process will also be critical. In the long run, the bet is that by hardening a subjective clinical decision into a software-guided protocol, Macuject can help standardize care for a leading cause of blindness, one retina at a time.

Sources

1. [Macuject.com] Macuject Company Website | https://www.macuject.com/
2. [Bionics Institute] From clinician to entrepreneur with Dr Devinder Chauhan - Bionics Institute | https://www.bionicsinstitute.org/podcasts-videos-media/from-clinician-to-entrepreneur-with-dr-devinder-chauhan/
3. [mivision 2021] Paying it Forward: A Free AI Solution to Improve Outcomes for nAMD - mivision | https://mivision.com.au/2022/05/paying-it-forward-a-free-ai-solution-to-improve-outcomes-for-namd/
4. [Crunchbase] Macuject Company Profile | https://www.crunchbase.com/organization/macuject
5. [Bradley Beddoes LinkedIn] Bradley Beddoes - Greater Brisbane Area | Professional Profile | LinkedIn | https://www.linkedin.com/in/bradleybeddoes/
6. [Medium Verge Healthtech] Why We Invested in Macuject | https://medium.com/verge-healthtech/why-we-invested-in-macuject-b9a937c150ed
7. [HealthTechAlpha] Macuject | https://www.healthtechalpha.com/venture/macuject
8. [Macuject.com/blog-pages/andhealth-plus] ANDHealth+ Blog | https://www.macuject.com/blog-pages/andhealth-plus
9. [mivision 2022] Paying it Forward: A Free AI Solution to Improve Outcomes for nAMD - mivision | https://mivision.com.au/2022/05/paying-it-forward-a-free-ai-solution-to-improve-outcomes-for-namd/
10. [CBInsights] Macuject CBInsights | https://www.cbinsights.com/company/macuject